BDX vs SOLV
BDX: A global medical technology leader providing essential healthcare supplies, diagnostic systems, and biosciences research tools to improve patient outcomes. SOLV: A diversified healthcare technology and medical products provider focused on improving patient outcomes through specialized clinical tools and healthcare software solutions.
Side-by-side fundamentals
| Metric | BDX | SOLV | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $182.75 | $86.41 | |
| Market cap | $49.8B | $14.7B | |
| P/E as of 2026-10-08 | 55.14 | 10.55 | SOLV lower |
| Net margin FY2025, SEC XBRL | +7.7% | +18.7% | SOLV higher |
| Gross margin FY2025, SEC XBRL | n/a | +53.5% | |
| Operating margin FY2025, SEC XBRL | +11.8% | +26.2% | SOLV higher |
| ROE FY2025, SEC XBRL | +6.6% | +30.8% | SOLV higher |
| ROA FY2025, SEC XBRL | +3.0% | +10.9% | SOLV higher |
| Debt / equity as of 2026-09-03 | 0.69 | 1.10 | BDX lower |
| Revenue growth (YoY) as of 2026-09-03 | -2.6% | -0.9% | SOLV higher |
| Revenue CAGR (3y) SEC XBRL | +5.0% | +0.8% | BDX higher |
| Dividend yield as of 2026-09-03 | +2.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | 13 | 0 | BDX higher |
| Beta as of 2026-09-03 | 0.45 | 0.86 | |
| 1-year return as of 2026-10-08 close | +19.9% | +19.3% | BDX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.